Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Having signed informed consent~* Age 18 to 75 years old~* Histologically confirmed gastric adenocarcinoma~* Unresectable recurrent or metastatic disease~* Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 12 months~* Measurable disease according to the RECIST criteria~* Karnofsky performance status ≥60~* Life expectancy of ≥2 month~* No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks~* ALT and AST\<2.5 times ULN (≤5 times ULN in patients with liver metastases)~* Serum albumin level ≥3.0g/dL~* Serum AKP \< 2.5 times ULN~* Serum creatinine \<1.5mg/dL~* Bilirubin level \< 1.5mg/dL~* Serum creatinine \<1.5 times ULN~* WBC\>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, Hb\>9g/dl~Exclusion Criteria:~* Brain metastasis (known or suspected)~* Previous systemic therapy for metastatic gastric cancer~* Inability to take oral medication~* Previous EGFR pathway-targeting therapy~* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry~* Heart failure, coronary artery disease, myocardial infarction within the last 6 months~* Known allergy to any study treatment~* Pregnancy or lactation period~* Any investigational agent within the past 28 days~* Other previous malignancy within 5 year, except non-melanoma skin cancer~* Previous adjuvant therapy with capecitabine+platinum~* Pre-existing neuropathy\>grade 1~* Legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- C225+Chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).